This week, a breakthrough for heart failure patients with mitral regurgitation emerges, prosthesis-patient mismatch raises the risk of death following TAVR, a new study challenges anticoagulation guidelines, and a possible blessing in disguise for rivaroxaban comes from the massive COMPASS trial. Subscribe to Cardiocast wherever you get your podcasts. Amazon Alexa Apple Podcasts